Madurai News

Uncomplicated Urinary Tract Infection Market Insight

 Breaking News
  • No posts were found

Uncomplicated Urinary Tract Infection Market Insight

August 23
13:05 2021
Uncomplicated Urinary Tract Infection Market Insight
DelveInsight Business Research LLP
DelveInsight’s ‘Uncomplicated Urinary Tract Infection Market’ report delivers an in-depth understanding of the Uncomplicated Urinary Tract Infection, historical and forecasted epidemiology as well as the Uncomplicated Urinary Tract Infection market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Uncomplicated Urinary Tract Infection Market

The Uncomplicated Urinary Tract Infection market report provides current treatment practices, emerging drugs, Uncomplicated Urinary Tract Infection market share of the individual therapies, current and forecasted Uncomplicated Urinary Tract Infection market size from 2018 to 2030 segmented by seven major markets. The Report also covers current Uncomplicated Urinary Tract Infection treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Uncomplicated Urinary Tract Infection Market Outlook

The Uncomplicated Urinary Tract Infection market size in the 7MM is expected to change during the study period 2018–2030. The therapeutic market of Uncomplicated Urinary Tract Infection in the seven major markets is expected to increase during the study period (2018–2030) with a CAGR of 10.8%. According to the estimates, the highest market size of Uncomplicated Urinary Tract Infection is found in the United States followed by Japan.

The United States Market Outlook

The total market size of Uncomplicated Urinary Tract Infection therapies in the United States is expected to increase with a CAGR of 11.6% in the study period (2018–2030).

EU-5 Countries: Market Outlook

The total market size of Uncomplicated Urinary Tract Infection therapies in EU-5 countries is expected to increase with a CAGR of 10.5% in the study period (2018–2030).

Japan Market Outlook

The total market size of Uncomplicated Urinary Tract Infection therapies in Japan is expected to increase with a CAGR of 7.1% in the study period (2018–2030).

Uncomplicated Urinary Tract Infection Pipeline Development Activities

The drugs which are in pipeline include:

  • GSK2140944/Gepotidacin (GlaxoSmithKline)
  • Sulopenem Etzadroxil – Probenecid (Iterum Therapeutics)
  • Uromune/MV140 (Inmunotek)
  • ExPEC Vaccine/ExPEC10V and ExPEC4V (Janssen Pharmaceuticals)
  • GSK3882347 (GlaxoSmithKline/Fimbrion Therapeutics)

Table of contents

1. Key Insights

2. Report Introduction

3. Uncomplicated Urinary Tract Infection Market Overview at a Glance

3.1. Market Share (%) Distribution of Uncomplicated Urinary Tract Infection in 2018

3.2. Market Share (%) Distribution of Uncomplicated Urinary Tract Infection in 2030

4. Executive Summary of Uncomplicated Urinary Tract Infection (uUTI)

4.1. Key Events

5. Epidemiology and Market Methodology

6. Disease Background and Overview

6.1. Introduction

6.2. Types of UTI

6.3. Signs and Symptoms of Uncomplicated UTI

6.4. Risk Factors and Causes of Uncomplicated UTI

6.5. Pathogenesis of UTI

6.6. Complications of UTI

7. Diagnosis of Uncomplicated UTI

7.1. Diagnostic algorithm

7.2. Clinical Examination

7.3. Lab Tests

7.4. Imaging and other tests

7.4.1. Cystoscopy

7.4.2. Ureteroscopy

7.5. Differential diagnosis

8. Prevention of UTI

9. Diagnostic Guidelines

9.1. European Association of Urology (EAU) Urological Infections Diagnostic Guidelines

9.2. American Urological Association (AUA) Guidelines

9.3. Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC)

10. Current Treatment Practices of Uncomplicated UTI

10.1. Treatment Algorithm

10.2. Antibiotic therapy

10.2.1. Uncomplicated cystitis

10.2.2. Uncomplicated pyelonephritis

10.2.3. Recurrent UTI

10.3. Antibiotic prophylaxis

11. Treatment Guidelines

11.1. American Urological Association (AUA) Guidelines

11.2. European Association of Urology (EAU) Urological Infections Treatment Guidelines

11.3. Comparison of AUA/CUA/SUFU and EAU Guidelines

11.4. National Institute for Health and Care Excellence (NICE) Guidelines

11.5. Infectious Diseases Society of America (IDSA), in collaboration with the European Society for Microbiology and Infectious Diseases (ESCMID) Guidelines

11.6. Guidelines of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC)

11.7. NICE – Antimicrobial prescribing strategy for lower UTI (also called cystitis)

12. Epidemiology and Patient Population

12.1. Key Findings

12.2. Epidemiology of Uncomplicated Urinary Tract Infection (uUTI)

12.3. Epidemiology Scenario

12.3.1. Total Occurrence-specific Cases of Uncomplicated Urinary Tract Infection

12.3.2. Total Diagnosed Cases of Uncomplicated Urinary Tract Infection

12.3.3. Total Age-specific Cases of Uncomplicated Urinary Tract Infection

12.3.4. Total Pathogen-specific Cases of Uncomplicated Urinary Tract Infection

12.3.5. Total Treated Cases (across lines) of Uncomplicated Urinary Tract Infection

13. Patient Journey

14. Key Endpoints in Uncomplicated UTI Clinical Trials

15. Emerging Therapies

15.1. GSK2140944 (Gepotidacin): GlaxoSmithKline

15.1.1. Product Description

15.1.2. Other Developmental Activities

15.1.3. Clinical Development

15.1.4. Safety and Efficacy

15.2. Sulopenem Etzadroxil – Probenecid: Iterum Therapeutics

15.2.1. Product Description

15.2.2. Other Developmental Activities

15.2.3. Clinical Development

15.2.4. Safety and Efficacy

15.3. Uromune (MV140): Inmunotek

15.3.1. Product Description

15.3.2. Other Developmental Activities

15.3.3. Clinical Development

15.3.4. Safety and Efficacy

15.4. ExPEC Vaccine (ExPEC10V and ExPEC4V): Janssen Pharmaceuticals

15.4.1. Product Description

15.4.2. Other Developmental Activities

15.4.3. Clinical Development

15.5. GSK3882347: GlaxoSmithKline/Fimbrion Therapeutics

15.5.1. Product Description

15.5.2. Other Developmental Activities

15.5.3. Clinical Development

16. Uncomplicated Urinary Tract Infection: 7 Major Market Analysis

16.1. Key Findings

16.2. Market Outlook

16.3. Market Size of Uncomplicated Urinary Tract Infection

16.3.1. Total Market Size of Uncomplicated Urinary Tract Infection

16.3.2. Market Size of Uncomplicated Urinary Tract Infection by Therapies

17. Market Access and Reimbursement

17.1. Key HTA decisions for Uncomplicated UTI

17.2. Reimbursement

17.3. Patient Access Programs

18. Market Drivers

19. Market Barriers

20. SWOT Analysis

21. Unmet Needs

22. Appendix

22.1. Bibliography

22.2. Report Methodology

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

Request for sample pages @ market size of Uncomplicated Urinary Tract Infection

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/